Evaluation of the efficacy of an internal teat sealer during the dry period

The efficacy of an internal dry period teat sealer containing bismuth subnitrate (Product A; Teatseal, Cross Vetpharm Group Ltd, Ireland) was compared with a long-acting antibiotic preparation containing cephalonium (Product B; Cepravin Dry Cow, Schering-Plough Ltd, UK), by assessing the number of new intramammary infections (IMI) acquired during the dry period and the number of cases of clinical mastitis during the first 100 d of lactation. Selection of study animals was based on historical data. No cases of clinical mastitis and all routine cow level somatic cell counts <200,000 cells/ml during the previous lactation were used to select cows likely to be uninfected with a major pathogen at drying off. Compared with the antibiotic tube, quarters that received the teat sealer acquired significantly fewer new IMI caused by Escherichia coli, all Enterobacteriaceae, and all major pathogens combined. There was no significant differences in the number of IMI caused by any other major pathogen. There was no significant difference in the severity or number of quarter or cow cases of clinical mastitis between product groups. Sixty quarters (3.2%) were infected with major pathogens at drying off, 27 (2.9%) in teat sealer and 33 (3.5%) in antibiotic tube cows. The dry period cure rate was not significantly different (63% product A, 70% product B). This is the first controlled study to demonstrate the efficacy of an internal bismuth teat sealer in protecting quarters against new dry period IMI caused by major mastitis pathogens, particularly environmental organisms, under UK field conditions.     

Complete versus selective dry cow therapy for mastitis control.

Two hundred and thirty-two cows were assigned alternately to complete dry cow therapy (infusion in all quarters on the day of drying off) or selective therapy (infusion in all quarters if a history of mastitis, California Mastitis Test score of +2 or +3 in any quarter, or if cell counts from bucket milk samples as determined by the membrane filter-deoxyribonucleic acid procedure were above 500,000 cells/ml). A dry cow product containing 10(6) units of procaine penicillin G and 1 g of dihydrostreptomycin in a slow release base was used. A 1% iodophor teat dip was used throughout the experiment. Infections of Staphylococcus aureus, Streptococcus agalactiae, other streptococci, and gram negative rods were eliminated from 85.4% of the infected quarters with complete therapy and 88.2% of the infected quarters with selective therapy. New infections occurred in 3.1% of quarters with complete therapy and in 6.5% of the quarters with selective therapy. Incidence of mastitis following the dry period was less with complete therapy compared to selective therapy (4.6% vs. 7.8% of the quarters). Selective therapy was as effective as complete therapy in eliminating existing infections. Complete therapy would be the choice in situations where new infections in dry period are of concern.     

Effectiveness of an internal teat seal in the prevention of new intramammary infections during the dry and early-lactation periods in dairy cows when used with a dry cow intramammary antibiotic

The objectives of this study were to determine the effect of infusion with an internal teat seal at dry off, when used as an adjunct to long-acting antibiotic infusion at dry off, on the risk for acquiring a new intramammary infection (IMI) during the dry period, prevalence of IMI and linear score (LS) after calving, and risk for experiencing a clinical mastitis event between dry off and 60 DIM. A total of 437 cows from 2 dairy herds, with no clinical mastitis and 4 functional quarters, were enrolled at dry off. Prior to the final milking, all quarters were sampled for bacteriological culture and SCC analysis. After milking, all 4 quarters were infused with a commercially available long-acting dry cow antibiotic. Two contralateral quarters were then infused with an internal teat seal (Orbeseal, Pfizer Animal Health, New York). Following calving the teat seal was stripped out at first milking. Duplicate milk samples were collected between 1 to 3 DIM and again between 6 to 8 DIM for culture and SCC analysis. Quarters treated with Orbeseal had significantly lower prevalence of IMI at 1 to 3 DIM (tx = 22.8%, control = 29.1%), had significantly fewer quarters that acquired a new IMI between dry off and 1 to 3 DIM (tx = 20.2%, control = 25.4%), and had significantly fewer quarters affected by a clinical mastitis event between dry off and 60 DIM (tx = 5.9%, control = 8.0%). Multivariable analysis showed a significant effect of treatment, with treated quarters being 30% less likely to develop a new IMI between dry off and 1 to 3 DIM, 31% less likely to have an IMI present at 1 to 3 DIM, 33% less likely to experience a clinical mastitis event between dry off and 60 DIM, and having significantly lower linear score measures at 1 to 3 DIM and 6 to 8 DIM, compared with control quarters.     

Effect of localised antibiotic infusions applied to the teat-canal and teat sinus at drying-off on mastitis in the dry-period and at calving

An experiment using three New Zealand herds and a total of 632 cows, examined the effect of localised prophylactic treatments with antibiotic at drying-off on the incidence of new intramammary infection during the dry period and at calving. Antibiotic was infused either into the teat canal (0.22 g of dry-cow formulation) or the teat sinus (3.1 g of lactating-cow formulation) of uninfected quarters to eliminate any bacteria present in these locations at the last milking of lactation. These treatments were compared with a negative control (nil treatment) and a positive antibiotic control (infusion of 3.6 g of dry-cow formulation). All antibiotic formulations used the same active ingredient, sodium cloxacillin. No significant reduction in new dry period clinical mastitis was observed for the two localised treatments whereas the positive control treatment achieved 100% reduction in new clinical mastitis compared with untreated control quarters. A 41% reduction (P < 0.05) in new Streptococcus uberis infections at calving was associated with the teat canal antibiotic treatment, compared with an 82% reduction (P < 0.001) for the positive antibiotic control. Both localised treatments showed a reduced incidence of new intramammary infection (P < 0.001) when pooled across periods and pathogens. Teats receiving either the teat canal antibiotic treatment or a full infusion of long acting dry-cow antibiotic had a lower incidence of open teat canals (P < 0.05) at 3 weeks after drying-off.     

Protection against Staphylococcus aureus mastitis in dairy cows using a bismuth-based teat seal containing the bacteriocin, lacticin 3147

We assessed the effectiveness of a novel dry cow treatment containing lacticin 3147 using deliberate challenge studies in lactating cows. Infection-free quarters of lactating cows were infused with Teat seal (Cross Vetpharm Group, Ltd., Dublin, Ireland) combined with the food-grade bacteriocin, lacticin 3147. Natural infection of the teat was simulated by deliberately introducing Staphylococcus aureus into the teat duct and teat sinus. Relative to control quarters, teat seal plus lacticin 3147 reduced the number of teats shedding viable cells when an inoculum of either approximately 1.7 x 10(3) or approximately 6.8 x 10(3) cfu per teat was used. In addition, the numbers of challenge organisms in those teats from which S. aureus was subsequently recovered were also reduced. However, when the concentration of bacteriocin in the teat seal formulation was reduced by approximately 50%, the number of teats shedding S. aureus cells was not reduced. These data indicate the potential for lacticin 3147 to prevent staphylococcal mastitis infections when a sufficient concentration of the bacteriocin is present. This study also highlights the application of a lactating-cow model to assess the effectiveness of antimicrobial intramammary products on mastitic cell populations.     

The use of a cephalonium containing dry cow therapy and an internal teat sealant, both alone and in combination

The dry period is a critical time in the lactation cycle, being the optimum time to cure existing intramammary infection (IMI) as well as encompassing the periods of highest susceptibility to new infection. Currently, IMI in the dry period is controlled with antibiotic dry cow therapy. The aim of this randomized control trial was to investigate different dry cow therapy regimens by stratifying cows by likely infection status at drying off in herds with low somatic cell count (SCC; bulk milk SCC <250,000 cells/mL) in southwest England. All quarters in 890 cows were recruited. The recruited cows were categorized as either infected or uninfected on the basis of SCC and clinical mastitis history. Ipsilateral quarters within each cow were randomly allocated to receive 1 of 4 different treatment regimens according to their infection category. Quarters in high-SCC infected cows were allocated to receive antibiotic dry cow therapy either alone or in combination with an internal teat sealant; quarters in low-SCC uninfected cows were allocated to receive teat sealant either alone or in combination with antibiotic dry cow therapy. All quarters were sampled for bacteriology at drying off and again within 10 d post-calving. Quarters were subsequently monitored for clinical mastitis for the first 100 d of lactation. The mass of residual sealant was assessed immediately post-calving to allow assessment of the association of sealant retention with treatment efficacy. Models were constructed to assess the efficacy of the different regimens in preventing IMI. Apparent cure rates of existing IMI with major pathogens were consistently >90% in quarters receiving antibiotic. Combination treatment of high-SCC infected cows resulted in an increased likelihood of being pathogen free post-calving (odds ratio = 1.40; 95% credibility interval = 1.03-1.90). The benefits of combination treatment of low-SCC uninfected cows were less clear. With respect to clinical mastitis, combination treatment of high-SCC infected cows resulted in a decreased likelihood of developing clinical mastitis in the first 100 d of the subsequent lactation (odds ratio = 0.68; 95% credibility interval = 0.48-0.98). The retention of the internal sealant was adversely affected by its use in combination with antibiotic dry cow therapy.     

Efficacy of a novel internal dry period teat sealant containing 0.5% chlorhexidine against experimental challenge with Streptococcus uberis in dairy cattle

The incidence of clinical mastitis and infection status at calving was assessed in quarters treated with 1 of 2 internal teat sealants at the time of dry off. Two contralateral quarters per cow (n = 63 cows) were treated with a sealant that contained 0.5% chlorhexidine; the other quarters were treated with a commercial teat sealant. Ten cows were untreated (controls). On d 2, 4, and 16 after dry off, cows were challenged with Streptococcus uberis S210 strain. Cows were examined daily for 34 d after drying off and cases of clinical mastitis were recorded. Milk samples were collected for culture from any quarters that developed clinical mastitis during the first 34 d after drying-off and from all quarters on d −5 and 0 relative to treatment and at the first and twentieth milking after calving. The incidence of clinical mastitis during the examination period was lower in treated quarters (n = 7/252; 1.5%; lower incidence for those treated with chlorhexidine-containing teat sealant n = 3/126; 1.2%) than in untreated quarters (n = 13/40; 26.8%). The protection against intramammary infection after calving, adjusted for the effect of cow, was higher in quarters treated with the novel teat sealant (89/105; 15.2%; 95% CI = 9.6-23.4) than in those treated with the commercial teat sealant (71/104; 31.7%; 95% CI = 23.5-41.3) and untreated controls (6/28; 78.6%; 95% CI = 59.8-90.0), respectively. Quarters treated with teat sealants were less likely to have an intramammary infection after calving and had a lower incidence of clinical mastitis during the early dry period than did untreated controls in this challenge study.     

Staphylococcus aureus and Streptococcus dysgalactiae in Norwegian herds after introduction of selective dry cow therapy and teat dipping

The objective was to promote a reduction in the prevalence of Staphylococcus aureus and Streptococcus dysgalactiae after 2 years of selective dry cow therapies and teat dipping/external teat sealant implementation. Three different dry cow treatments, one long-acting and two short-acting penicillin-based products were tested at herd level together with a negative control teat dipping group, an iodine teat dipping group and DryFlextrade mark, an external teat sealant. The regimes were independently randomly allocated to 178 dairy herds. Yearly bacteriological quarter milk samples were collected from all cows at the beginning of the trial, after 1 year and 2 years. At herd level, a total of 15% of the herds showed no Staphylococcus aureus isolates after 2 years, compared with 5% at the beginning. The distribution of Streptococcus dysgalactiae infected herds remained the same after 2 years. At cow level, there were no significant differences in the reduction of Staph. aureus between the different dry cow therapies and teat dipping regimes. But there was a significant reduction of Str. dysgalactiae in the iodine teat dipping group compared with Dryflextrade mark and the negative control group. The proportional rate of Staph. aureus positive quarters was reduced from 65.9% to 54.9% after 2 years. As for Str. dysgalactiae, an increase was observed from 14.2% to 15.2%.     

Prevention of bovine mastitis by a postmilking teat disinfectant containing chlorous acid and chlorine dioxide in a soluble polymer gel

A natural exposure study was conducted in a herd of 150 lactating dairy cows for 18 mo to determine the effectiveness of chlorous acid and chlorine dioxide in a soluble polymer gel as a postmilking teat disinfectant for the prevention of bovine mastitis. Right quarters of cows were dipped in the experimental teat dip after milking machine removal. Left quarters were not dipped and served as within-cow negative controls. The experimental teat dip reduced Staphylococcus aureus infections 67.4%, Streptococcus dysgalactiae infections 63.8%, and Streptococcus uberis infections 27.8%. Overall efficacy of the chlorous acid and chlorine dioxide teat dip against major mastitis pathogens was 52.2%. The experimental teat dip reduced Corynebacterium bovis infections and coagulase-negative staphylococcal infections also by 45.8 and 38.7%, respectively. Overall efficacy against minor mastitis pathogens was 43.4%. Under conditions of this trial, the experimental teat dip containing chlorous acid and chlorine dioxide was effective in preventing new intramammary infections against a variety of mastitis pathogens.     

Control of new intramammary infection at calving by prepartum teat dipping

Cows were subjected to teat dipping in a commercial iodophor germicide twice daily for at least 7 days immediately before calving to assess efficacy of the practice in reducing new intramammary infection at calving. In a cold season and in a warm season, groups of about 35 cows successively calving were treated and were compared with similarly sized and selected control groups. There were no advantages for teat dipped over control cow groups for incidence of new intramammary infections at calving, for new infections that persisted for longer than 14 days after calving, or for new infections that required antibiotic therapy. Incidence of new infection in warm weather (27.3% of quarters) was twice that in cool weather (13.6%). The most frequently isolated pathogens were coagulase-negative staphylococci and Streptococcus uberis. Staphylococcus aureus infections were most likely to persist into the new lactation (83%) than were infections by other pathogens (38 to 57%).     

Comparison of tilmicosin and cephapirin as therapeutics for Staphylococcus aureus mastitis at dry-off

Forty-four cows (26 Jerseys and 18 Holsteins) that had at least 1 mammary quarter that was naturally (n = 12) or experimentally (n = 84) infected with Staphylococcus aureus were allotted to three treatment groups of approximately equal number at the end of lactation. Cows were dried off by abrupt cessation of milking, and dry cow therapy was administered as an intramammary infusion of cephapirin benzathine at 10 ml per quarter, an intramammary infusion of tilmicosin (solution containing 300 mg/ml) at 5 ml per quarter, or a subcutaneous injection of tilmicosin at 5 mg/kg of body weight on the day of drying off and another injection 4 d later. Mammary secretions were monitored during the dry period and postpartum for antimicrobial residues, intramammary infection (IMI) status, and somatic cell counts. Results demonstrated the following percentage cures for IMI caused by Staph. aureus at 28 d postcalving based on individual mammary quarters: cephapirin benzathine, 78.1%; tilmicosin infused, 74.2%; and tilmicosin injected, 9.1%. During the first 4 wk after drying off, the mean concentration of tilmicosin in mammary secretions from cows infused with the antibiotic remained approximately 10-fold higher than that in secretions from cows injected with the antibiotic (3.43 vs. 0.32 ppm), and, by the time of calving, concentrations for cows treated with both methods were below the dilution limit of the assay (< 0.1 ppm). Results demonstrated that intramammary infusion of tilmicosin was equally as effective as cephapirin benzathine in curing IMI caused by Staph. aureus at drying off; however, the subcutaneous injection of tilmicosin at the dose used was not effective as a dry cow therapeutic against Staph. aureus.     

Activation of immune cells in bovine mammary gland secretions by zymosan-treated bovine serum

Mastitis, caused by bacterial infection of the mammary gland, is a major disease of dairy cattle. The greatest risks of intramammary infection occur at the end of lactation and at the initiation of the next lactation when the cow calves. Treating serum with zymosan (yeast cell wall preparation) causes the complement to cleave, allowing this serum to serve as a source of complement fragment 5a (C5a), a potent chemoattractant and activator of the immune system. Our hypothesis was that intramammary infusion of zymosan-treated serum (ZTS) would recruit polymorphonuclear neutrophils (PMN) and generate prolonged activity in lymphocytes within the mammary gland. Ultimately this could help prevent bacterial infections in cows at dry-off and at the initiation of lactation. Two ipsilateral quarters of the mammary gland of each cow were infused with ZTS (12.5 mL/quarter), and 2 contralateral quarters were infused with saline in 8 cows shortly after lactation ended. Mammary secretions were collected periodically throughout the dry period and the first 2 wk of the next lactation. Activation status of lymphocytes and PMN in those secretions was assessed based on the intracellular presence or absence of IFN-γ and IL-8 as determined by flow cytometry. The ZTS infusion greatly increased PMN numbers in mammary secretions for the first week only. The percentage of IFN-γ positive lymphocytes and PMN, and the percentage of IL-8 positive PMN, exhibited a sustained increase in secretions from ZTS-treated quarters through the first 2 wk of lactation. The ZTS can stimulate PMN and lymphocyte-mediated immune defense mechanisms in the mammary gland, which may provide a useful means of preventing new intramammary infections during the dry period as well as at the initiation of lactation.     

California Mastitis test guide of selective dry cow therapy

California Mastitis Test scores and bacteriological analysis of quarter foremilk samples from 133 cows of three herds were used to determine which quarters or cows to treat in a selective dry cow therapy program. Effect of score, week of the test, and type and number of intramammary infections were examined. Score was independent of the type of intramammary pathogen infection. When all positive reactions were considered, approximately 80% of the infections by major pathogens were diagnosed on a single milk sample taken at either 8 or 4 wk before drying off. At 8 and 4 wk, 13 and 23% of samples from uninfected quarters or quarters infected with minor pathogens had positive reactions. Selective treatment of all cows that had one or more positive quarters led to treatment of twice as many quarters than if only positive quarters were treated. The most discriminating, simplest, and economic method of selective treatment was one test on quarter foremilk samples collected 8 wk before the expected dry-off and dry treatment of all positive mammary quarters.     

Evaluation of the use of dry cow antibiotics in low somatic cell count cows

The goal of dry cow therapy (DCT) is to reduce the prevalence of intramammary infections (IMI) by eliminating existing IMI at drying off and preventing new IMI from occurring during the dry period. Due to public health concerns, however, preventive use of antibiotics has become questionable. This study evaluated selective DCT in 1,657 cows with low somatic cell count (SCC) at the last milk recording before drying off in 97 Dutch dairy herds. Low SCC was defined as <150,000 cells/mL for primiparous and <250,000 cells/mL for multiparous cows. A split-udder design was used in which 2 quarters of each cow were treated with dry cow antibiotics and the other 2 quarters remained as untreated controls. The effect of DCT on clinical mastitis (CM), bacteriological status, SCC, and antibiotic use were determined at the quarter level using logistic regression and chi-squared tests. The incidence rate of CM was found to be 1.7 times (95% confidence interval = 1.4–2.1) higher in quarters dried off without antibiotics as compared with quarters dried off with antibiotics. Streptococcus uberis was the predominant organism causing CM in both groups. Somatic cell count at calving and 14 d in milk was significantly higher in quarters dried off without antibiotics (772,000 and 46,000 cells/mL, respectively) as compared with the quarters dried off with antibiotics (578,000 and 30,000 cells/mL, respectively). Quarters with an elevated SCC at drying off and quarters with a positive culture for major pathogens at drying off had a higher risk for an SCC above 200,000 cells/mL at 14 d in milk as compared with quarters with a low SCC at drying off and quarters with a negative culture for major pathogens at drying off. For quarters that were culture-positive for major pathogens at drying off, a trend for a higher risk on CM was also found. Selective DCT, not using DCT in cows that had a low SCC at the last milk recording before drying off, significantly increased the incidence rate of CM and SCC. The decrease in antibiotic use by drying off quarters without DCT was not compensated by an increase in antibiotic use for treating CM. Total antibiotic use related to mastitis was reduced by 85% in these quarters.     

Increased susceptibility to intramammary infection following removal of teat canal keratin.

Influence of teat canal keratin on susceptibility to intramammary infection was investigated in lactating Jersey cows. In each of two replicate trials, keratin was removed from the left teats of 20 cows immediately before milking. Immediately after milking, all teats were exposed to bacterial challenge by immersion in a suspension of Streptococcus agalactiae (5 x 10(7) cfu/ml). Bacterial challenge was repeated after the next four milkings. Foremilk samples were obtained for 8 d after keratin removal to determine infection status. A mammary quarter was classified as infected based solely upon the bacteriological criteria outlined by the National Mastitis Council. The rate of infection in quarters from which keratin was removed was greater than that in control quarters. Infection rates were 26.3% for keratin-removed quarters and 8.3% for control quarters in trial 1 and 13.5 and 0%, respectively, in trial 2. When more stringent criteria (recovery of greater than 100 cfu of S. agalactiae/ml in three or more successive milk samples and a SCC of greater than 10(6)) were used to identify a subset of infections that were clearly intramammary, infection rates were 9.3% for keratin-removed quarters and 1.4% for control quarters. Thus, partial removal of keratin from the teat canal compromised the ability of the teat to prevent passage of bacterial pathogens from the external environment into the mammary gland.     

Efficacy of a cephapirin dry cow product for treatment of experimentally induced Staphylococcus aureus mastitis in heifers.

A dry cow product containing 300 mg of cephapirin benzathine was evaluated in pregnant and nonpregnant Jersey heifers for its effect on experimentally induced Staphylococcus aureus mastitis. Cephapirin was detectable in mammary secretion of nonpregnant heifers for up to 5 wk and in tissue for 1 wk after intramammary infusion. Staphylococcus aureus was not detectable in tissue and secretion of treated quarters at 1 and 3 wk but was not eliminated from two quarters of one heifer tested at 6 wk posttreatment. Histologic evaluation of mammary tissue from nonpregnant heifers revealed significant differences in leukocytosis between uninfected and S. aureus-infected quarters but no differences in epithelium, lumen, and stroma, indicating no difference in secretion potential or glandular development. Twenty-five pregnant Jersey heifers were experimentally infected in two quarters with S. aureus 12 to 14 wk prepartum. After 1 to 3 wk, 13 heifers were infused in 21 S. aureus-infected quarters with a commercial cephapirin dry cow product. Nine infected quarters were left untreated. All treated quarters were bacteriologically negative both at calving and through 2 mo after calving. Of the 9 infected quarters not treated prepartum, 1 spontaneously cured and 2 became non-functional. The remaining quarters were treated at calving with a commercial cephapirin lactating cow product. Of these, 3 cured and 3 failed to resolve.     

Effect of 2 herbal intramammary products on milk quantity and quality compared with conventional and no dry cow therapy

Dry cow therapy, administered at the end of lactation, is aimed at eliminating current and preventing future intramammary (IMM) bacterial infections and typically involves intramammary administration of antibiotics. Certified organic dairies in the United States are restricted from using antibiotics and must consider an alternative therapy or no dry cow therapy. The current study compared 2 herbal products to conventional dry cow therapy and no treatment for a total of 5 treatments over 2 trials. Trial 1 was conducted over 3 yr on 1 research farm and trial 2 included 4 commercial farms plus the research herd over 2 yr. Treatments included (1) a conventional IMM antibiotic and internal teat sealant (penicillin-dihydrostreptomycin and bismuth subnitrate; CON); (2) an herbal IMM product purported to act as a teat sealant (Cinnatube, New AgriTech Enterprises, Locke, NY; CIN); (3) an herbal IMM product (Phyto-Mast, Bovinity Health LLC, Narvon, PA; P-M); (4) Phyto-Mast and Cinnatube (PC); or (5) no dry cow therapy (NT). Each treatment group was balanced by breed, lactation number, due date, herd, and year. However, the CON treatment was used only in the research herd because of the intent to avoid antibiotic usage on the other 4 farms. Comparisons among treatments included the difference between pre- and posttreatment 305-d mature equivalent milk production (trial 1), somatic cell score change from dry-off to freshening at the cow and quarter levels (trials 1 and 2), and milk microbiology change over the dry period (trial 2). We detected no significant differences among treatments for milk yield differences between the lactation following treatment and the lactation preceding treatment. Changes in somatic cell score from one lactation to the next also did not differ significantly among treatments in either trial. Cure rates were not significantly different among treatments; only 19.6% of all quarters were infected at dry off. The proportion of quarters with new infections at 3 to 5 d postcalving did not significantly differ among treatments, except between CIN and NT. Percentages (least squares means ± standard error) of quarters with new infections were 24 ± 21% for CON, 15 ± 7% for CIN, 30 ± 10% for P-M, 32 ± 11% for PC, and 35 ± 11% for NT. The efficacy of the herbal products was similar to that of conventional therapy, and the herbal products had no apparent adverse effects.     

Mastitis control: a discussion

Methods of mastitis control that are effective against Streptococcus agalactiae and Staphylococcus aureus have been developed and proven successful. These control procedures, however, are not as effective against the environmental pathogens. Environmental pathogens are predominantly the coliform bacteria and species of streptococci other than Streptococcus agalactiae. The total extent of their present involvement in mastitis is not well documented, and this is due in part to differences in the nature of infection by environmental pathogens compared to Streptococcus agalactiae and Staphylococcus aureus infections. Concern regarding the importance of environmental pathogens in mastitis is increasing. This concern is based, first, on current trends of dairy cattle housing and management that increase exposure to teat ends to environmental pathogens and, second, on a reduction of prevalence of Streptococcus agalactiae and Staphylococcus aureus infected quarters. The latter is a result of the effectiveness of postmilking teat end disinfection and dry cow therapy. Development of equally effective control methods for the environmental pathogens will be an important area of future mastitis research.     

Observations on Corynebacterium bovis infection of the bovine mammary gland. I. Natural infection

Data from experiments in 55 commercial herds have been examined to study the patterns of Corynebacterium bovis infection. Such infections are most common in herds that are not subjected to regular control methods but their commercial significance appears to be small. In herds using teat disinfection and dry cow therapy levels of infection with this organism are low. There is no evidence from these data to suggest that C. bovis infections protect the udder against invasion by a major pathogen. On the contrary these infections do not persist when major pathogens invade.     

Invited review: Selective use of antimicrobials in dairy cattle at drying-off

Administering intramammary antimicrobials to all mammary quarters of dairy cows at drying-off [i.e., blanket dry cow therapy (BDCT)] has been a mainstay of mastitis prevention and control. However, as udder health has considerably improved over recent decades with reductions in intramammary infection prevalence at drying-off and the introduction of teat sealants, BDCT may no longer be necessary on all dairy farms, thereby supporting antimicrobial stewardship efforts. This narrative review summarizes available literature regarding current dry cow therapy practices and associated impacts of selective dry cow therapy (SDCT) on udder health, milk production, economics, antimicrobial use, and antimicrobial resistance. Various methods to identify infections at drying-off that could benefit from antimicrobial treatment are described for selecting cows or mammary quarters for treatment, including utilizing somatic cell count thresholds, pathogen identification, previous clinical mastitis history, or a combination of criteria. Selection methods may be enacted at the herd, cow, or quarter levels. Producers' and veterinarians' motivations for antimicrobial use are discussed. Based on review findings, SDCT can be adopted without negative consequences for udder health and milk production, and concurrent teat sealant use is recommended, especially in udder quarters receiving no intramammary antimicrobials. Furthermore, herd selection should be considered for SDCT implementation in addition to cow or quarter selection, as BDCT may still be temporarily necessary in some herds for optimal mastitis control. Costs and benefits of SDCT vary among herds, whereas impacts on antimicrobial resistance remain unclear. In summary, SDCT is a viable management option for maintaining udder health and milk production while improving antimicrobial stewardship in the dairy industry.